Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Using the 2019 EULAR/ACR Classification Criteria to Predict Disease Severity in SLE

Lara C. Pullen, PhD  |  November 30, 2021

Predicting a patient’s disease course is difficult, especially in SLE. A recent study examined the link between a patient’s 2019 EULAR/ACR SLE Classification Criteria score at diagnosis to subsequent disease severity, finding a score of 20 or more may predict a more severe disease course.

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Classification CriteriaSLEsystemic lupus erythematosus (SLE)

Joint Venture: 2021 Updates in Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  November 24, 2021

An update on the state of RA management was presented by Dr. Bryant England, a co-author of the 2021 ACR Guideline on the Management of Rheumatoid Arthrits, during the Review Course held during ACR Convergence 2021.

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2021ACR Convergence 2021 – RA

The Many Facets of COVID-19: Experts Address Basic & Clinical Research Concepts in the COVID-19 Era

Jason Liebowitz, MD, FACR  |  November 23, 2021

New concepts in autoimmunity & immunology are being discovered daily in research being conducted to understand the SARS-CoV-2 virus and its implications for rheumatology & all fields of medicine. Here are some insights shared by experts during day 1 of the Basic and Clinical Research Conference.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2021COVID-19Multisystem Inflammatory Syndrome in Children (MIS-C)U.S. Food and Drug Administration (FDA)vaccine hesitancy

Gout, Imaging & Cardiovascular Disease: 2 Experts Discuss Challenging Patients & Advanced Imaging

Samantha C. Shapiro, MD  |  November 23, 2021

Experts compare using ultrasound and dual-energy computed tomography (DECT) scan when diagnosing likely gout patients, and discuss the latest insights into the intersection between gout and cardiovascular disease.

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence – GoutACR Convergence 2021Goutimaging

Research Helps Explain Idiosyncrasies of COVID-19

Jason Liebowitz, MD, FACR  |  November 23, 2021

The Basic and Clinical Research Conference session on Rheumatology Complications of Emerging Viral Infections/SARS-CoV-2 presented findings from numerous studies that help explain some of the idiosyncrasies of COVID-19.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2021COVID-19interferonMultisystem Inflammatory Syndrome in Children (MIS-C)

Clinical Rheumatology Year in Review 2021

Samantha C. Shapiro, MD  |  November 22, 2021

ACR Convergence 2021—On Nov. 5, Karen H. Costenbader, MD, MPH, professor of medicine, Harvard Medical School, and director of the lupus program, Brigham and Women’s Hospital, Boston, gave a whirlwind review of the most important clinical rheumatology publications of the past year. Testing New Medications for Rheumatic Disease ADVOCATE Trial of Avacopan Dr. Costenbader first…

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone DisordersResearch RheumRheumatoid ArthritisVasculitis Tagged with:ACR Convergence 2021ACR Convergence 2021 – RAClinicalClinical researchJAK inhibitorsjakinibsJanus Kinase InhibitorsKnee Osteoarthritis (OA)stepped exercise

Lupus often presents with a butterfly rash.

Top 12: Research in Systemic Lupus Erythematosus at a Glance

David S. Pisetsky, MD, PhD  |  November 18, 2021

Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.

Filed under:ACR ConvergenceConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLE

FDA Approves First Interchangeable Biosimilar to Adalimumab, Plus a Combination Drug Approved

Michele B. Kaufman, PharmD, BCGP  |  November 17, 2021

Cyltezo (adalimumab-adbm) may be interchanged for Humira (adalimumab) for all indications, according to an October decison by the FDA. The FDA has also approved a new combination of celecoxib and tramadol for pain management.

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:adalimumabadalimumab-adbmBiosimilarscelecoxib (Elyxyb)interchangeabilityPain Managementtramadol

Tumor Necrosis Factor Inhibitors May Slow the Progression of Spondyloarthritis

Lara C. Pullen, PhD  |  November 16, 2021

Recent research indicates tumor necrosis factor inhibitors may slow disease progression in the spine of patients with axial spondyloarthritis.

Filed under:Axial SpondyloarthritisConditions Tagged with:axial spondyloarthritis (SpA)TNFtumor necrosis factor (TNF) inhibitorstumor necrosis factor inhibitor (TNFi)

The 2021 ACR Masters

Patrice Fusillo  |  November 14, 2021

Recognition as an ACR Master is one of the highest honors the College bestows. The designation of Master is conferred on ACR members, age 65 or older by Oct. 1 of the year in which they are nominated, who have made outstanding contributions to the ACR and the field of rheumatology through scholarly achievement and/or…

Filed under:ACR ConvergenceMeeting Reports Tagged with:ACR Convergence 2021Dr. Alan N. BaerDr. Alex LimanniDr. Daniel F. BattafaranoDr. David A. McLainDr. Gary S. FiresteinDr. Joanne M. JordanDr. Joel A. BlockDr. John G. HanlyDr. John J. CushDr. Maarten BoersDr. Oliver FitzGeraldDr. Paula MarchettaDr. Robert A. ColbertDr. W. Winn ChathamDr. Yukiko Kimura

  • « Previous Page
  • 1
  • …
  • 58
  • 59
  • 60
  • 61
  • 62
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences